CompletedPhase 4NCT02625389
A Study to Evaluate How Safe and Effective is the Mixture of Lipiodol® Ultra Fluid and Glue When Used for Embolization Procedures
Studying Angiosarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Guerbet
- Principal Investigator
- Jing Hao, MDGuerbet
- Intervention
- Lipiodol Ultra Fluid with surgical glues(drug)
- Enrollment
- 132 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2017 – 2021
Study locations (16)
- Division of Peripheral Vascular & Endovascular sciences, Medanta-The Medicity Hospital, Gurgaon, Haryana, India
- Mahatma Gandhi Missions Medical college and Hospital, Aurangabad, India
- KLES Dr. Prabhakar Kore Hospital, Belagavi, India
- Victoria Hospital, Bengaluru, India
- Mazumdar Shaw medical Centre, Bengaluru, India
- Apollo Hospital, Hyderabad, India
- AIIMS, Jodhpur, India
- Sanjay Gandhi Post Graduate Institute of Meducal Sciences (SGPGI), Lucknow, India
- Government Medical College, Nagpur, India
- BLK Super Speciality Hospital, New Delhi, India
- AIIMS, New Delhi, India
- B.J Govt College & Sassoon Hospitals, Pune, India
- KEM Hospital, Pune, India
- 7 Orange Hospitals, Pune, India
- Geetanjali Medical College and Hospital, Udaipur, India
- +1 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02625389 on ClinicalTrials.govOther trials for Angiosarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06898970Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for AngiosarcomaVarun Monga, MBBS
- RECRUITINGPHASE2NCT07007273Pembrolizumab for Advanced Cutaneous Sarcomas Not Including AngiosarcomaH. Lee Moffitt Cancer Center and Research Institute
- RECRUITINGNCT06715579Cardiac Angiosarcoma International RegistryImmune Oncology Research Institute
- RECRUITINGPHASE2NCT06849986IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)Fudan University
- RECRUITINGPHASE2NCT06673628Pembrolizumab Plus Lenvatinib in Unresectable Cutaneous Angiosarcoma PatientsNational Cancer Center, Japan
- RECRUITINGPHASE1NCT06440005A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid TumorsAngiex, Inc.
- RECRUITINGNCT06375941Prospective Observational Study of Localized Angiosarcoma of Any Site: ProStarsItalian Sarcoma Group
- RECRUITINGNCT06541652A French Multicenter Observational Retrospective Study of Rare Primary Liver CancersFederation Francophone de Cancerologie Digestive